Breaking News Instant updates and real-time market news.

AVRO

Avrobio

$18.27

-0.77 (-4.04%)

07:08
03/25/19
03/25
07:08
03/25/19
07:08

Avrobio 'on track' for two additional gene therapy programs in 2019

In October 2018, AVROBIO received a no objection letter from Health Canada to the clinical trial application for GAU-201, its Phase 1/2 clinical trial of AVR-RD-02 in Gaucher disease. The company subsequently received two additional NOLs from Health Canada to CTA amendments that incorporate elements of the plato platform into the trial. Dosing is expected to begin in the second half of 2019. In December 2018, the FDA accepted the Investigational New Drug application for an investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 in cystinosis. This trial will be led by Stephanie Cherqui, PhD, Associate Professor of Pediatrics at the University of California, San Diego, and is expected to begin in the second half of 2019.

AVRO Avrobio
$18.27

-0.77 (-4.04%)

10/09/18
GUGG
10/09/18
INITIATION
GUGG
Buy
Avrobio initiated with a Buy at Guggenheim
Guggenheim analyst Whitney Ijem initiated Avrobio with a Buy rating and $35 price target, calling the two-day 61% sell off on the company's Ph1 Fabry data update an overreaction.
11/27/18
LEER
11/27/18
INITIATION
Target $27
LEER
Market Perform
Avrobio initiated with a Market Perform at Leerink
Leerink analyst Mani Foroohar initiated Avrobio with a Market Perform rating and a price target of $27.
11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
01/17/19
LEER
01/17/19
NO CHANGE
Target $19
LEER
Market Perform
Avrobio price target lowered to $19 from $27 at Leerink
Leerink analyst Mani Foroohar lowered his price target for Avrobio to $19 from $27, while reiterating a Market Perform rating on the shares. While the analyst is positive on recent additions to senior management, he is more conservative on the market opportunity for Fabry gene therapy given the need for higher-intensity preconditioning regimens than the company has used previously, and believes that the potential adoption of value-based annuity pricing models by the industry could pose further risk to Avrobio's bottom line.

TODAY'S FREE FLY STORIES

04:15
12/12/19
12/12
04:15
12/12/19
04:15
General news
FX Action: USD-CAD dove yesterday »

FX Action: USD-CAD dove…

01:55
12/12/19
12/12
01:55
12/12/19
01:55
General news
Asian Market Update: »

Asian Market Update:…

BILL

Bill.com

$0.00

(0.00%)

23:41
12/11/19
12/11
23:41
12/11/19
23:41
Syndicate
Bill.com 9.824M share IPO priced at $22.00 »

The deal size was raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

FTSV

Forty Seven

$36.00

1.4 (4.05%)

23:39
12/11/19
12/11
23:39
12/11/19
23:39
Syndicate
Forty Seven 4.86M share Spot Secondary priced at $35.00 »

Morgan Stanley and Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NCR

NCR Corp.

$32.60

0.16 (0.49%)

20:34
12/11/19
12/11
20:34
12/11/19
20:34
Hot Stocks
NCR enters consent decree to resolve claims related to Kalamazoo River matter »

NCR Corporation announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CIEN

Ciena

$35.45

0.75 (2.16%)

, LOVE

Lovesac

$14.49

0.05 (0.35%)

20:25
12/11/19
12/11
20:25
12/11/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CIEN

Ciena

$35.45

0.75 (2.16%)

LOVE

Lovesac

$14.49

0.05 (0.35%)

VERU

Veru

$2.47

0.17 (7.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 17

    Dec

  • 19

    Dec

CHEF

Chefs' Warehouse

$35.51

-0.06 (-0.17%)

20:24
12/11/19
12/11
20:24
12/11/19
20:24
Initiation
Chefs' Warehouse initiated at Piper Jaffray »

Chefs' Warehouse…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

HSBC

HSBC

$37.15

0.44 (1.20%)

20:13
12/11/19
12/11
20:13
12/11/19
20:13
Upgrade
HSBC rating change at BofA/Merrill »

HSBC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLCE

Children's Place

$54.36

-16.31 (-23.08%)

19:54
12/11/19
12/11
19:54
12/11/19
19:54
Downgrade
Children's Place rating change at Wedbush »

Children's Place…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

LVGO

Livongo Health

$27.55

1.48 (5.68%)

19:43
12/11/19
12/11
19:43
12/11/19
19:43
Syndicate
Livongo Health 2.78M share Secondary priced at $27.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CVX

Chevron

$116.22

-1.68 (-1.42%)

19:42
12/11/19
12/11
19:42
12/11/19
19:42
Periodicals
Chevron said to be close to approving Gulf of Mexico project, Bloomberg says »

Bloomberg's Kevin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$233.00

0.03 (0.01%)

19:27
12/11/19
12/11
19:27
12/11/19
19:27
Hot Stocks
RH CEO sold 500,000 common shares of company from Dec 9 through Dec 11 »

RH announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWD

Crowdstrike

$47.74

0.18 (0.38%)

19:17
12/11/19
12/11
19:17
12/11/19
19:17
Hot Stocks
Crowdstrike CFO sells 215K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 09

    Dec

GLD

SPDR Gold Shares

$138.94

0.98 (0.71%)

19:00
12/11/19
12/11
19:00
12/11/19
19:00
Hot Stocks
SPDR Gold Shares holdings rise to 886.22MT from 885.93MT »

This is the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$147.70

1.58 (1.08%)

, GOOG

Alphabet

$1,345.14

0.64 (0.05%)

18:59
12/11/19
12/11
18:59
12/11/19
18:59
Periodicals
Disney Plus was Google's most searched term in U.S. this year, TechCrunch says »

In the United States in…

DIS

Disney

$147.70

1.58 (1.08%)

GOOG

Alphabet

$1,345.14

0.64 (0.05%)

GOOGL

Alphabet Class A

$1,344.65

1.61 (0.12%)

AAPL

Apple

$270.71

2.09 (0.78%)

T

AT&T

$38.17

0.1 (0.26%)

NFLX

Netflix

$299.25

6.04 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 29

    Jan

DLHC

DLH Holdings

$4.58

0.525 (12.96%)

, FORM

FormFactor

$23.77

0.57 (2.46%)

18:57
12/11/19
12/11
18:57
12/11/19
18:57
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: DLH…

DLHC

DLH Holdings

$4.58

0.525 (12.96%)

FORM

FormFactor

$23.77

0.57 (2.46%)

LULU

Lululemon

$233.31

3.75 (1.63%)

NX

Quanex

$19.72

0.68 (3.57%)

TLRD

Tailored Brands

$4.85

-0.42 (-7.97%)

NDSN

Nordson

$167.44

1.69 (1.02%)

MESA

Mesa Air

$9.25

0.17 (1.87%)

OXM

Oxford Industries

$74.07

-1.89 (-2.49%)

AKTS

Akoustis

$7.60

0.11 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 18

    Dec

TTD

Trade Desk

$250.44

0.13 (0.05%)

18:57
12/11/19
12/11
18:57
12/11/19
18:57
Hot Stocks
Trade Desk CEO: We don't own any media »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RACE

Ferrari

$165.20

0.37 (0.22%)

18:45
12/11/19
12/11
18:45
12/11/19
18:45
Hot Stocks
Ferrari enters into new EUR 350M credit facility »

Ferrari announces that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIBT

RiceBran

$2.09

-0.105 (-4.79%)

18:43
12/11/19
12/11
18:43
12/11/19
18:43
Syndicate
RiceBran offers to sell common stock, no amount given »

Lake Street Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$151.00

2.27 (1.53%)

, TSLA

Tesla

$352.40

3.58 (1.03%)

18:42
12/11/19
12/11
18:42
12/11/19
18:42
Hot Stocks
VMware's Poonen: Our networking business is on fire »

In an interview on…

VMW

VMware

$151.00

2.27 (1.53%)

TSLA

Tesla

$352.40

3.58 (1.03%)

DELL

Dell Technologies

$47.73

0.37 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 07

    Jan

  • 08

    Jan

  • 09

    Jan

  • 27

    Feb

SMTC

Semtech

$47.36

0.48 (1.02%)

18:38
12/11/19
12/11
18:38
12/11/19
18:38
Hot Stocks
Semtech director sells 19.3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CS

Credit Suisse

$12.95

-0.115 (-0.88%)

18:29
12/11/19
12/11
18:29
12/11/19
18:29
Periodicals
Former Credit Suisse JV exec claims she was put under surveillance, WSJ says »

Colleen Graham, a former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

PANW

Palo Alto Networks

$226.76

1.71 (0.76%)

18:22
12/11/19
12/11
18:22
12/11/19
18:22
Hot Stocks
Palo Alto Networks CEO: No systematic problem with our sales »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

PBYI

Puma Biotechnology

$8.71

0.24 (2.83%)

18:08
12/11/19
12/11
18:08
12/11/19
18:08
Hot Stocks
Puma Biotechnology presents Phase II results of neratinib in breast cancer »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTHX

G1 Therapeutics

$23.06

-0.18 (-0.77%)

18:05
12/11/19
12/11
18:05
12/11/19
18:05
Hot Stocks
G1 Therapeutics presents data from Phase 1b/2a trial of lerociclib at SABCS »

G1 Therapeutics reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.